STK36: a potential prognostic biomarker in hepatocellular carcinoma
Year: 2026
Type: article
Abstract: BACKGROUND: STK36, a member of the serine/threonine kinase family, has been reported to be highly expressed in cancers. However, there have been fewer reports on the expression and role of STK36 in hepatocellular carcinoma (HCC). METHODS: We used the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases to evaluate the differential expression of STK36 in HCC and normal tissues. Immunohistochemistry (IHC) and quantitative real-time reverse transcription polymerase chain reaction(qRT-PCR) validated the expression of STK36 in HCC. The chi-square test was employed to study the relationship between STK36 and clinical characteristics. The prognostic significance of STK36 expression was analyzed using Kaplan-Meier and Cox regression methods. We also studied the association between STK36 and immunity. We discussed STK36 expression at the single-cell and spatial transcriptome distribution levels. Drug sensitivity analysis was utilized to discuss the link between STK36 expression and small-molecule drugs. Gene Set Enrichment Analysis (GSEA) was used to discuss the function of STK36 in HCC. RESULTS: STK36 expression was elevated in HCC from the TCGA and ICGC databases. IHC and qRT-PCR confirmed the overexpression of STK36 in HCC. STK36 expression had a positive correlation with T stage (tumor stage). STK36 expression was an independent prognostic factor affecting HCC patients' outcomes. A relationship existed between STK36 expression and the infiltration of immune cells as well as immune checkpoints. Single-cell and spatial transcriptome analyses demonstrated that STK36 was upregulated in HCC. GSEA showed that STK36 was involved in some pathways, including ECM-receptor interaction, cell cycle, etc. CONCLUSION: STK36 acts as a potential prognostic index in HCC, serves as a potential biomarker for predicting response to immunotherapy, and provides a rationale for further functional studies.
Source: BMC Cancer
Authors: Ting Liu, Yanyong Ma, Zhizhao Li, Xuan Zhou
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,390
Awards: G4022711766, G7051864610
OpenAlex ID: W7202038301
